Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649549 | 0.91 | SSTR3 (0.42) | SSTR3FOLH1CTSLHTR2AHDAC8 | |
| SCHEMBL26015675 | 0.90 | HTR2A (0.40) | SSTR3FOLH1HTR2ASIRT1SIRT2 | |
| SCHEMBL14129704 | 0.87 | SSTR3 (0.48) | SSTR3FOLH1HDAC8SIRT1SIRT2 | |
| SCHEMBL26015579 | 0.84 | ITGB1 (0.43) | FOLH1HDAC8ITGB1ITGA5 | |
| SCHEMBL29649584 | 0.83 | FOLH1 (0.40) | SSTR3FOLH1CTSL | |
| SCHEMBL16450919 | 0.83 | SSTR3 (0.49) | SSTR3CTSLHTR2AHDAC8SIRT1 | |
| SCHEMBL29649540 | 0.83 | FOLH1 (0.45) | SSTR3FOLH1 | |
| SCHEMBL29589720 | 0.83 | SSTR3 (0.36) | SSTR3FOLH1HTR2ASIRT1SIRT2 | |
| SCHEMBL29649444 | 0.82 | FOLH1 (0.39) | SSTR3FOLH1CTSL | |
| SCHEMBL26015581 | 0.81 | FOLH1 (0.38) | FOLH1SIRT1SIRT2SIRT5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | SSTR3 3591/4885FOLH1 433/4885CTSL 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.